版本:
中国

BRIEF-Ultragenyx seizure drug fails mid-stage study

March 22 Ultragenyx Pharmaceutical Inc -

* Ultragenyx announces topline data from phase 2 UX007 glucose transporter type-1 deficiency syndrome seizure study

* Study did not meet primary endpoint

* Patients treated with UX007 demonstrated a reduction of 13.4% in overall seizure frequency relative to placebo

* There was no difference in cognitive function as assessed by cantab in patients treated with UX007 compared to placebo

* Two of 36 enrolled patients discontinued treatment during eight-week placebo-controlled period

* 12 patients have discontinued treatment during extension period to date

* Two patients discontinued due to adverse events, 4 patients due to tolerability reasons, and 8 due to compliance or study burden issues

* Ultragenyx Pharmaceutical Inc - "Look forward to studying UX007 in our phase 3 study in Glut1 DS patients with movement disorders"

* Ultragenyx Pharmaceutical Inc - "Continue to evaluate our plans in seizure indication" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐